CTLA4 and colitis: The cardiovascular, hematologic, renal, neurologic, and musculoskeletal systems are not as commonly affected.35–42 Colitis is associated with better prognosis compared to pneumonitis.55,56 Dermatologic irAEs are typically seen two to three weeks after therapy initiation, followed by the GI system at six to seven weeks, and the endocrine system at nine to ten weeks.35–42,56 Severe irAEs associated with anti-CTLA-4 medications occur earlier compared to anti-PD-1/PD-L1 medications.35–45 Laboratory and imaging assessment depend on the specific organ involved.